ArticleNature communications2022

Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer.

Kai Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.